Watchlist

Watchlist
Affimed N.V. (AFMD)
Affimed's lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27%
Thinly traded nano cap Affimed N.V. ( AFMD -26.9% ) slumps on more than a 4x surge in volume on the heels of its announcement of interim results from a Phase 1b clinical trial assessing lead candidate AFM13 combined with Merck's KEYTRUDA (pembrolizumab) in patients with relapsed/refrac…
Midday Gainers / Losers
Gainers: YTEN +215% . DAVE +32% . NETE +32% . SSC +24% . BPMC +23% . BLUE +23% . OSTK +21% . CLSD +21% . GROW +19% . RIOT +19% . More news on: Yield10 Bioscience, Inc., Famous Dave's of America, Inc., Net Element International, Inc., Stocks on the move, …
Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q3 2017 Results - Earnings Call Transcript
Affimed Therapeutics (AFMD) Q3 2017 Results Earnings Conference Call November 07, 2017, 8:30 AM ET Executives Anca Alexandru Head-Communications Adi Hoess Chief Executive Officer Florian Fischer Chief Financial Officer Analysts Yale Jen L…
Affimed Therapeutics 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Affimed Therapeutics in conjunction with their 2017 Q3 earnings Read more …
Affimed reports Q3 results
Affimed (NASDAQ: AFMD ): Q3 EPS of -0.18 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more …
Notable earnings before Tuesday's open
AAWW , AFMD , AGEN , ALLT , ASIX , ATHM , ATRO , ATRS , BCRX , BLD , CBM , CBOE , CCE , CRIS , CROX , DEA , DF , DNR , EMR , EXPD , GLDD , HAE , HAIN , HCN , HL , HLNE , IONS , JELD , LABL , LGIH , LNCE , LXP , MTRX , MZOR , NS , ONCE , PNK , PRIM , RC…
Affimed (AFMD) Presents At LEERINK Partners Roundtable Series On Rare Disease And Immuno-Oncology - Slideshow
The following slide deck was published by Affimed Therapeutics in conjunction with this Read more …
Affimed N.V. (AFMD) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
The following slide deck was published by Affimed Therapeutics in conjunction with this Read more …
Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q2 2017 Results - Earnings Call Transcript
Affimed Therapeutics (AFMD) Q2 2017 Earnings Conference Call August 1, 2017 8:30 AM ET Executives Anca Alexandru Head of Communications Adi Hoess Chief Executive Officer Florian Fischer Chief Financial Officer Analysts Maury Raycroft Jeff…
Affimed Therapeutics 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by Affimed Therapeutics in conjunction with their 2017 Q2 earnings Read more …
Affimed reports Q2 results
Affimed (NASDAQ: AFMD ): Q2 EPS of -0.18 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more …
Affimed N.V. (AFMD)